awmsg logo



colestilan (BindRen®)


Reference No. 1592

Publication date:
31/10/2014


Appraisal information

colestilan (BindRen®) 1 g film-coated tablet
colestilan (BindRen®) 2 g granules
colestilan (BindRen®) 3 g granules


Company: Mitsubishi Tanabe Pharma Europe Ltd
BNF category: Nutrition and blood
NMG meeting date: 10/09/2014
AWMSG meeting date: 08/10/2014
   
   
Submission Type: Full Submission
Status: Marketing authorisation withdrawn
Advice No: 3014
Ratification by Welsh Government: 30/10/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

LICENCE WITHDRAWN. Please refer to the European Medicines Agency website for further information. Colestilan (BindRen®) is not recommended for use within NHS Wales for the treatment of hyperphosphataemia in adult patients with chronic kidney disease stage 5 receiving haemodialysis or peritoneal dialysis. The case for cost-effectiveness has not been proven.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download